Symbols / VYNE
VYNE Chart
About
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 19.15M |
| Enterprise Value | -13.69M | Income | -33.79M | Sales | 524.00K |
| Book/sh | 1.01 | Cash/sh | 0.99 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.52 | PEG | — |
| P/S | 36.54 | P/B | 0.57 | P/C | — |
| EV/EBITDA | — | EV/Sales | -26.13 | Quick Ratio | 8.09 |
| Current Ratio | 8.87 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.79 | EPS next Y | -1.10 | EPS Growth | — |
| Revenue Growth | 39.70% | Earnings | 2025-11-06 08:00 | ROA | -41.51% |
| ROE | -70.67% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -46.11% | Profit Margin | 0.00% | Shs Outstand | 33.29M |
| Shs Float | 32.23M | Short Float | 1.65% | Short Ratio | 0.95 |
| Short Interest | — | 52W High | 2.86 | 52W Low | 0.28 |
| Beta | 2.03 | Avg Volume | 5.35M | Volume | 289.51K |
| Target Price | $2.00 | Recom | None | Prev Close | $0.60 |
| Price | $0.58 | Change | -3.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.00
Mean price target
2. Current target
$0.58
Latest analyst target
3. DCF / Fair value
$-15.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.58
Low
$2.00
High
$2.00
Mean
$2.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-07-30 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-04-25 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-12-23 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-18 | init | BTIG | — → Buy | $8 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-06-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-02-29 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-10-30 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2023-05-12 | main | Cantor Fitzgerald | — → Overweight | $9 |
| 2023-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
- VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
- VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders - The AI Journal Wed, 17 Dec 2025 08
- New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan Wed, 17 Dec 2025 08
- Vyne Therapeutics stock soars after merger with Yarrow Bioscience - Investing.com Wed, 17 Dec 2025 08
- Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock - Fierce Biotech Wed, 30 Jul 2025 07
- Clinical roundup: Cardiff, VYNE and NewAmsterdam share trial updates across three disease areas - FirstWord Pharma Wed, 30 Jul 2025 07
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) - PR Newswire Wed, 17 Dec 2025 08
- VYNE Therapeutics and Yarrow Bioscience Announce Merger to Advance YB-101 for Graves' Disease and Thyroid Eye Disease - Quiver Quantitative Wed, 17 Dec 2025 08
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today? - TipRanks Wed, 30 Jul 2025 07
- VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints - Investing.com Wed, 30 Jul 2025 07
- VYNE's Vitiligo Drug Shows Mixed Results: 43% Improvement in High-Dose Group Despite Trial Miss - Stock Titan Wed, 30 Jul 2025 07
- VYNE Therapeutics Announces Merger with Yarrow Bioscience - TipRanks Wed, 17 Dec 2025 08
- VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance Mon, 18 Aug 2025 07
- VYNE and Yarrow Bioscience to merge in all-stock transaction - Investing.com Wed, 17 Dec 2025 08
- VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance hu, 14 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1145 | 927 | — | Stock Award(Grant) at price 0.81 per share. | HARSCH MUTYA FONTE | General Counsel | — | 2025-06-02 00:00:00 | D |
| 1 | 8681 | 7032 | — | Stock Award(Grant) at price 0.81 per share. | DOMZALSKI DAVID T | Chief Executive Officer | — | 2025-06-02 00:00:00 | D |
| 2 | 15000 | 43800 | — | Purchase at price 2.92 per share. | LEPORE PATRICK G | Director | — | 2025-01-15 00:00:00 | D |
| 3 | 3901 | 11547 | — | Stock Award(Grant) at price 2.96 per share. | DOMZALSKI DAVID T | Chief Executive Officer | — | 2024-11-29 00:00:00 | D |
| 4 | 4429 | 9562 | — | Stock Award(Grant) at price 2.16 per share. | DOMZALSKI DAVID T | Chief Executive Officer | — | 2024-05-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.01 |
| NormalizedEBITDA | -43.63M | -29.26M | -34.22M | -38.94M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -39.81M | -27.87M | -33.95M | -44.21M |
| ReconciledDepreciation | 4.00K | 0.00 | 72.00K | 109.00K |
| ReconciledCostOfRevenue | 3.35M | |||
| EBITDA | -43.63M | -29.26M | -34.22M | -38.94M |
| EBIT | -43.64M | -29.26M | -34.30M | -39.05M |
| NetInterestIncome | 0.00 | -5.61M | ||
| InterestExpense | 0.00 | 5.61M | ||
| NormalizedIncome | -39.81M | -27.87M | -33.95M | -44.21M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -39.83M | -28.45M | -23.21M | -73.33M |
| TotalExpenses | 44.14M | 29.68M | 34.77M | 39.84M |
| TotalOperatingIncomeAsReported | -43.64M | -29.26M | -34.30M | -38.91M |
| DilutedAverageShares | 42.59M | 10.27M | 3.19M | 2.86M |
| BasicAverageShares | 42.59M | 10.27M | 3.19M | 2.86M |
| DilutedEPS | -0.93 | -2.78 | -7.28 | -25.56 |
| BasicEPS | -0.93 | -2.78 | -7.28 | -25.56 |
| DilutedNIAvailtoComStockholders | -39.83M | -28.45M | -23.21M | -73.33M |
| NetIncomeCommonStockholders | -39.83M | -28.45M | -23.21M | -73.33M |
| NetIncome | -39.83M | -28.45M | -23.21M | -73.33M |
| NetIncomeIncludingNoncontrollingInterests | -39.83M | -28.45M | -23.21M | -73.33M |
| NetIncomeDiscontinuousOperations | -27.00K | -580.00K | 10.73M | -29.12M |
| NetIncomeContinuousOperations | -39.81M | -27.87M | -33.95M | -44.21M |
| TaxProvision | 4.00K | 0.00 | 13.00K | -448.00K |
| PretaxIncome | -39.80M | -27.87M | -33.93M | -44.66M |
| OtherIncomeExpense | 3.83M | 1.39M | 363.00K | -135.00K |
| OtherNonOperatingIncomeExpenses | 3.83M | 1.39M | 363.00K | -135.00K |
| SpecialIncomeCharges | 0.00 | |||
| ImpairmentOfCapitalAssets | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 0.00 | -5.61M | ||
| InterestExpenseNonOperating | 0.00 | 5.61M | ||
| OperatingIncome | -43.64M | -29.26M | -34.30M | -38.91M |
| OperatingExpense | 44.14M | 29.68M | 34.77M | 39.84M |
| ResearchAndDevelopment | 30.95M | 16.31M | 18.39M | 19.54M |
| SellingGeneralAndAdministration | 13.19M | 13.38M | 16.39M | 20.30M |
| GeneralAndAdministrativeExpense | 13.19M | 13.38M | 16.39M | |
| OtherGandA | 13.19M | 13.38M | 16.39M | |
| GrossProfit | 11.41M | |||
| CostOfRevenue | 3.35M | |||
| TotalRevenue | 501.00K | 424.00K | 477.00K | 931.00K |
| OperatingRevenue | 501.00K | 424.00K | 477.00K | 931.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 14.83M | 14.10M | 3.23M | 2.98M |
| ShareIssued | 14.83M | 14.10M | 3.23M | 2.98M |
| TotalDebt | 99.00K | 214.00K | 0.00 | 349.00K |
| TangibleBookValue | 52.09M | 88.73M | 31.20M | 48.64M |
| InvestedCapital | 52.09M | 88.73M | 31.20M | 48.64M |
| WorkingCapital | 49.62M | 88.42M | 28.93M | 44.78M |
| NetTangibleAssets | 52.09M | 88.73M | 31.20M | 48.64M |
| CapitalLeaseObligations | 99.00K | 214.00K | 0.00 | 349.00K |
| CommonStockEquity | 52.09M | 88.73M | 31.20M | 48.64M |
| TotalCapitalization | 52.09M | 88.73M | 31.20M | 48.64M |
| TotalEquityGrossMinorityInterest | 52.09M | 88.73M | 31.20M | 48.64M |
| StockholdersEquity | 52.09M | 88.73M | 31.20M | 48.64M |
| GainsLossesNotAffectingRetainedEarnings | 20.00K | 26.00K | 0.00 | 0.00 |
| OtherEquityAdjustments | 20.00K | 26.00K | ||
| RetainedEarnings | -731.17M | -691.34M | -662.74M | -639.52M |
| AdditionalPaidInCapital | 783.24M | 780.04M | 693.94M | 688.16M |
| CapitalStock | 1.00K | 1.00K | 0.00 | 5.00K |
| CommonStock | 1.00K | 1.00K | 0.00 | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 14.82M | 8.95M | 9.56M | 18.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 1.41M | 211.00K | 0.00 |
| OtherNonCurrentLiabilities | 1.31M | |||
| PreferredSecuritiesOutsideStockEquity | 0.00 | 211.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 99.00K | 0.00 | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 99.00K | 0.00 | 0.00 |
| CurrentLiabilities | 14.82M | 7.54M | 9.35M | 18.41M |
| OtherCurrentLiabilities | 1.31M | |||
| CurrentDebtAndCapitalLeaseObligation | 99.00K | 115.00K | 349.00K | |
| CurrentCapitalLeaseObligation | 99.00K | 115.00K | 0.00 | 349.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.43M | 1.65M | 2.58M | 2.96M |
| PayablesAndAccruedExpenses | 11.98M | 5.78M | 6.77M | 15.10M |
| CurrentAccruedExpenses | 9.27M | 4.12M | 4.38M | 8.59M |
| Payables | 2.71M | 1.66M | 2.39M | 6.51M |
| AccountsPayable | 2.71M | 1.66M | 2.39M | 6.51M |
| TotalAssets | 66.91M | 97.69M | 40.76M | 67.05M |
| TotalNonCurrentAssets | 2.47M | 1.72M | 2.48M | 3.86M |
| OtherNonCurrentAssets | 2.26M | 1.51M | 2.48M | 3.51M |
| NonCurrentPrepaidAssets | 2.48M | 3.51M | ||
| NetPPE | 206.00K | 207.00K | 0.00 | 354.00K |
| AccumulatedDepreciation | -4.00K | 0.00 | -551.00K | |
| GrossPPE | 210.00K | 207.00K | 0.00 | 905.00K |
| Leases | 0.00 | 59.00K | ||
| OtherProperties | 53.00K | |||
| MachineryFurnitureEquipment | 117.00K | 0.00 | 793.00K | |
| BuildingsAndImprovements | 93.00K | 207.00K | 0.00 | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 64.44M | 95.96M | 38.27M | 63.19M |
| OtherCurrentAssets | 2.92M | 2.66M | 2.30M | 4.90M |
| AssetsHeldForSaleCurrent | 0.00 | 7.84M | ||
| RestrictedCash | 0.00 | 54.00K | 67.00K | 605.00K |
| PrepaidAssets | 2.13M | 4.57M | ||
| Inventory | 7.29M | |||
| FinishedGoods | 3.96M | |||
| WorkInProcess | 33.00K | |||
| RawMaterials | 3.30M | |||
| Receivables | 0.00 | 5.00M | 7.58M | |
| DuefromRelatedPartiesCurrent | 0.00 | 5.00M | 0.00 | |
| AccountsReceivable | 173.00K | 7.58M | ||
| CashCashEquivalentsAndShortTermInvestments | 61.52M | 93.25M | 30.91M | 42.25M |
| OtherShortTermInvestments | 41.59M | 62.63M | 0.00 | 0.00 |
| CashAndCashEquivalents | 19.93M | 30.62M | 30.91M | 42.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -34.09M | -25.34M | -29.20M | -56.37M |
| RepurchaseOfCapitalStock | 0.00 | -360.00K | ||
| RepaymentOfDebt | 0.00 | -36.43M | ||
| IssuanceOfCapitalStock | 0.00 | 82.82M | 1.68M | 75.98M |
| CapitalExpenditure | -117.00K | |||
| InterestPaidSupplementalData | 0.00 | 2.38M | ||
| EndCashPosition | 19.93M | 30.67M | 30.98M | 42.85M |
| BeginningCashPosition | 30.67M | 30.98M | 42.85M | 58.42M |
| EffectOfExchangeRateChanges | 0.00 | |||
| ChangesInCash | -10.75M | -301.00K | -11.88M | -15.56M |
| FinancingCashFlow | -141.00K | 82.39M | 1.65M | 39.78M |
| CashFlowFromContinuingFinancingActivities | -141.00K | 82.39M | 1.65M | 39.78M |
| NetOtherFinancingCharges | -294.00K | |||
| ProceedsFromStockOptionExercised | -141.00K | -67.00K | -28.00K | 522.00K |
| NetPreferredStockIssuance | 0.00 | -360.00K | 211.00K | 0.00 |
| PreferredStockPayments | 0.00 | -360.00K | ||
| PreferredStockIssuance | 211.00K | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 82.82M | 1.47M | 75.98M |
| CommonStockIssuance | 0.00 | 82.82M | 1.47M | 75.98M |
| NetIssuancePaymentsOfDebt | 0.00 | -36.43M | ||
| NetLongTermDebtIssuance | 0.00 | -36.43M | ||
| LongTermDebtPayments | 0.00 | -36.43M | ||
| InvestingCashFlow | 23.36M | -57.35M | 15.67M | 1.03M |
| CashFlowFromContinuingInvestingActivities | 23.36M | -57.35M | 15.67M | 1.03M |
| NetInvestmentPurchaseAndSale | 23.48M | -62.35M | 0.00 | 1.03M |
| SaleOfInvestment | 84.00M | 0.00 | 0.00 | 1.03M |
| PurchaseOfInvestment | -60.52M | -62.35M | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | 5.00M | 15.67M | 0.00 |
| SaleOfBusiness | 0.00 | 5.00M | 15.67M | 0.00 |
| NetPPEPurchaseAndSale | -117.00K | 0.00 | 0.00 | |
| PurchaseOfPPE | -117.00K | 0.00 | 0.00 | |
| OperatingCashFlow | -33.97M | -25.34M | -29.20M | -56.37M |
| CashFlowFromContinuingOperatingActivities | -33.97M | -25.34M | -29.20M | -56.37M |
| ChangeInWorkingCapital | 5.00M | 60.00K | 2.28M | 4.78M |
| ChangeInOtherCurrentLiabilities | -114.00K | 214.00K | -349.00K | -1.21M |
| ChangeInOtherCurrentAssets | 0.00 | 841.00K | ||
| ChangeInPayablesAndAccruedExpense | 6.01M | -559.00K | -8.68M | -2.67M |
| ChangeInPayable | 6.01M | -559.00K | -8.68M | -2.67M |
| ChangeInAccountPayable | 6.01M | -559.00K | -8.68M | -2.67M |
| ChangeInInventory | 0.00 | 97.00K | 113.00K | |
| ChangeInReceivables | -899.00K | 405.00K | 11.21M | 7.71M |
| ChangesInAccountReceivables | -899.00K | 405.00K | 11.21M | 7.71M |
| OtherNonCashItems | 2.47M | |||
| StockBasedCompensation | 3.30M | 3.31M | 4.30M | 8.08M |
| UnrealizedGainLossOnInvestmentSecurities | -1.00K | 1.00K | 0.00 | |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -2.44M | -255.00K | 0.00 | |
| DepreciationAmortizationDepletion | 4.00K | 0.00 | 72.00K | 109.00K |
| DepreciationAndAmortization | 4.00K | 0.00 | 72.00K | 109.00K |
| Depreciation | 4.00K | 0.00 | 72.00K | 109.00K |
| OperatingGainsLosses | -12.64M | 1.52M | ||
| GainLossOnSaleOfPPE | 0.00 | 282.00K | 93.00K | |
| GainLossOnSaleOfBusiness | 0.00 | -12.92M | 0.00 | |
| NetIncomeFromContinuingOperations | -39.83M | -28.45M | -23.21M | -73.33M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VYNE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|